<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01863277</url>
  </required_header>
  <id_info>
    <org_study_id>0130-12</org_study_id>
    <nct_id>NCT01863277</nct_id>
  </id_info>
  <brief_title>Safety Study of Melatonin in Stroke Patients</brief_title>
  <official_title>A Double Blind, Placebo Controlled Study to Evaluate the Efficacy of Melatonin in Acute Ischemic Stroke.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wolfson Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wolfson Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the effect of Melatonin (in a dosage of 14mg daily)
      for a better clinical outcome in the period three days post stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stroke is the third most common cause of stroke. The cascade of event is separated into
      hyperacute,,acute,sub-acute and chronic. In the acute, sub acute state there are mechanisms
      of inflammation apoptotic death and effect of free radicals. Melatonin was proved to effect
      these mechanisms and to have a favourable effect in different diseases. The aim of the study
      is to prove That the use of Melatonin in a higher dosage may have a anti-destructive effect
      in stoke.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of at least one point on the MRS score</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Melatonin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Melatonin 14mg/daily given over 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>sugar pill given over 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <arm_group_label>Melatonin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  within 72hours of ischemic stroke

          -  age 18-80

          -  both gender

          -  ability to sign consent form

        Exclusion Criteria:

          -  intra-cerebral bleeding

          -  tumour of brain

          -  multiple sclerosis

          -  s/p craniotomy

          -  known allergy to melatonin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>E. Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yair Lampl, Prof</last_name>
      <phone>+972-3-5028513</phone>
      <email>y_lampl@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Mary Israelson</last_name>
      <phone>+972-507-704618</phone>
      <email>maryisraelson@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yair Lampl, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2013</study_first_submitted>
  <study_first_submitted_qc>May 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2013</study_first_posted>
  <last_update_submitted>May 24, 2013</last_update_submitted>
  <last_update_submitted_qc>May 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wolfson Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Yair Lampl</investigator_full_name>
    <investigator_title>Prof. Yair Lampl</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

